Abstract
Over the last decade, the class of the atypical antipsychotics has become the gold standard for the treatment of bipolar disorder (BD), at least for its manic/mixed phases. This phenomenon has different explanations: first, the number of compounds with formal approvals for BD is higher in comparison with other mood-stabilizers including lithium and anticonvulsants. Second, the sample size of randomized controlled trials assessing the efficacy and safety of different pharmacological treatments is usually larger for most recently approved compounds (i.e., atypical agents for the treatment of BD). If the role of atypical antipsychotics is well-established in the treatment of BD, doubts still persist about their optimal efficacy as monotherapy vs combination treatment with other mood-stabilizers, in particular. In addition, a possible superiority in terms of efficacy for polytherapy needs to be balanced in relation to tolerability issues. The present article was aimed to review the state of the art in the field reviewing the latest evidence arising from international guidelines recommendations and meta-analyses.
Keywords: Bipolar disorder, atypical antipsychotics, monotherapy, combination therapy
Current Psychopharmacology
Title:Use of Atypical Antipsychotics as Mono/Polytherapy with Mood Stabilizers for the Treatment of Bipolar Disorder. An Update
Volume: 2
Author(s): A. Carlo Altamura, Beatrice Benatti and Bernardo Dell’Osso
Affiliation:
Keywords: Bipolar disorder, atypical antipsychotics, monotherapy, combination therapy
Abstract: Over the last decade, the class of the atypical antipsychotics has become the gold standard for the treatment of bipolar disorder (BD), at least for its manic/mixed phases. This phenomenon has different explanations: first, the number of compounds with formal approvals for BD is higher in comparison with other mood-stabilizers including lithium and anticonvulsants. Second, the sample size of randomized controlled trials assessing the efficacy and safety of different pharmacological treatments is usually larger for most recently approved compounds (i.e., atypical agents for the treatment of BD). If the role of atypical antipsychotics is well-established in the treatment of BD, doubts still persist about their optimal efficacy as monotherapy vs combination treatment with other mood-stabilizers, in particular. In addition, a possible superiority in terms of efficacy for polytherapy needs to be balanced in relation to tolerability issues. The present article was aimed to review the state of the art in the field reviewing the latest evidence arising from international guidelines recommendations and meta-analyses.
Export Options
About this article
Cite this article as:
Carlo Altamura A., Benatti Beatrice and Dell’Osso Bernardo, Use of Atypical Antipsychotics as Mono/Polytherapy with Mood Stabilizers for the Treatment of Bipolar Disorder. An Update, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010047
DOI https://dx.doi.org/10.2174/2211556011302010047 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Editorial (Thematic Issue: The Multidomain Mobility Lab in Older Persons: From Bench to Bedside)
Current Pharmaceutical Design Ajulemic Acid (CT3) A Potent Analog of the Acid Metabolites of THC
Current Pharmaceutical Design Cardiovascular Effects of Omega-3 Free Fatty Acids.
Current Vascular Pharmacology Everyday Cognition Scale Items that Best Discriminate Between and Predict Progression From Clinically Normal to Mild Cognitive Impairment
Current Alzheimer Research Diagnosis of Renal Diseases Based on Machine Learning Methods Using Ultrasound Images
Current Medical Imaging Nicotine and Gastrointestinal Disorders: Its Role in Ulceration and Cancer Development
Current Pharmaceutical Design Gene Therapy for Immunologic Tolerance: Using Bone Marrow-Derived Cells to Treat Autoimmunity and Hemophilia
Current Stem Cell Research & Therapy Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design A comparative <i>in vivo</i> Evaluation of Anti-Alzheimer Activity of Bacopa Extract and its Solid Lipid Nanoparticles
Current Bioactive Compounds The Role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: Effectiveness in 522 Patients with Bipolar Depression, Mixed-state, Mania and Catatonic Features
Current Neuropharmacology Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease
Current Alzheimer Research The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Targeting Fatty Acid Metabolism in the Treatments of Obesity and Disorders of CNS Cellular Energy Balance
Central Nervous System Agents in Medicinal Chemistry Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders
Current Alzheimer Research Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Alzheimers Disease Burdens African-Americans: A Review of Epidemiological Risk Factors and Implications for Prevention and Treatment
Current Psychiatry Reviews Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms
Current Drug Targets Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer’s Disease
Current Alzheimer Research Molecular Docking Studies of Some Novel Antidepressant 5-Substituted Phenyl-3-(Thiophen-2-yl)-4, 5-Dihydro-1h-Pyrazole-1-Carboxamides Against Monoamine Oxidase Isoforms
Central Nervous System Agents in Medicinal Chemistry